Dr. Tejinder Singh

Work Experience

✔ Practicing in the field of Medical Oncology since last 18ys

✔ Given more than 50000+ chemotherapy/targeted therapies/immunotherapyand treated more than 100000+ patients since last 18+ yrs.

✔ Have given many lectures,seminars,moderation in both international and national conferences and also organizing since last 7 years Annual Gastrointestinal Symposium (which is a national level oncology conference)

✔ Being part of many clinical trials’ and having multiple publications in both national and international journals.

✔ Being in the advisory board of many multinational and national pharmaceutical companies

✔ Undergone training in medical oncology from Kidwai Memorial institute of Oncology,Bangalore and also from Tata Memorial Hospital,Mumbai

✔ Have special interest in treatment of breast, thoracic, brain, liver, Gastrointestinal, lymphomas,leukemias,bone and soft tissue cancers

✔ Had privilege of starting Department of Medical Oncology in Apollo Hospital, Navi Mumbai, Fortis Hiranandani hospital, Vashi and Fortis hospital Kalyan

✔ Privileged to be the first qualified medical oncologist based in Navi Mumbai.

✔ And also qualified DNB Medical Oncology teacher and examiner and first one from Navi Mumbai

✔ In Apollo hospital,Navi Mumbai, I impart medical oncology training to DNB students.

✔ I am FOUNDER and Director of Oncoheal Clinic,Vashi,Navi Mumbai

✔ Jan 2017 till date:Sr Consultant Medical Oncologist,Apollo Hospital,Navi Mumbai

✔ April 2012 till date: Assistant Professor and Head, Dept of Medical Oncology, Padmashree Dr.D.Y.Patil Medical College, Nerul, Navi Mumbai

✔ Oct 2011 till July 2019: Consultant Medical Oncology, Fortis Hiranandini Hospital, Vashi, Mumbai

✔ Feb 2010 till date: Reviewer of journal INDIAN PAEDIATRICS

✔ Dec 2010 till July 2019: Consultant Medical Oncology, Fortis Hospital, Mulund, Mumbai

✔ Dec 2010 till July 2019: Consultant Medical Oncology, Fortis Hospital, Kalyan, Maharashtra

✔ August 2010 till Dec 2010: Consultant Medical Oncology, Apollo Hospital, Bangalore

✔ Oct 2010 till Dec 2010: Visiting Consultant Medical Oncology, Apollo Hospital, Mysore

✔ Sep 2007 to July 2010: Senior Resident, Department of Medical Oncology,

✔ Kidwai Memorial Institute of Oncology, Bangalore, India.

✔ 1^st Aug 2007 to 31^st 2007: Senior Resident, Department of Medical Oncology, Tata Memorial Hospital, Mumbai, India.

✔ Feb 2007 to July 2007: Lecturer, Department of Medicine, Dr.D.Y.Patil Medical College, Navi Mumbai, India.

✔ Aug 2006 to Jan 2007: Clinical Assistant, Medical Oncology, P.D.Hinduja Hospital, Mumbai, India

✔ Dec 200-Jan 2006: Resident, Department of Medicine, B.Y.L Nair hospital and T.N.Medical College, Mumbai, India.

✔ Feb 2002 to Nov 2002: Resident, Department of ENT, B.Y.L Nair hospital and T.N.Medical College, Mumbai, India.

✔ Aug 2001 to Jan 2002: Resident Medical Officer, Guru Nanak Hospital, Bandra, Mumbai.

Education

Doctorate: DM (Medical Oncology), Kidwai Memorial Institute of Oncology, Rajiv Gandhi University of Health Sciences, Bangalore, India from 2007-2010.
Masters: MD (Internal Medicine) from T N Medical college, B Y L Nair hospital, University of Mumbai, India from 2003 – 2006
Bachelors in Medicine, Bachelors in Surgery: MBBS from Thanjavur Medical College, Thanjavur, Dr.M.G.R.Medical University, Tamil Nadu, India from 1993– 1999

Training

Certificate course in Essentials of Palliative Care (Basics), Indian Association of Palliative Care, Jan 2010.

Clinical placement in Palliative Care Certificate, Indian Association of Palliative Care, March 2010 (gives license to stock and dispense oral morphine in India)

Publications: Book Chapter

Etiology and Pathogenesis of Multiple Myeloma. Education book of CME on plasma cell dyscrasias 2009, KMIO, Bangalore, India

Publications-First author

Floor of mouth metastases in colorectal cancer-case report. Annals of Saudi Medicine. Jan 2011 issue. 31(1):87-89
• Primary Bone Lymphoma-A report of 2 cases and review of the literature. Journal of Cancer Research and Therapeutics. July-Sept 2010.Vol 6.Issue 3.Page 296-298.
• LANGERHAN’S CELL HISTIOCYTOSIS: A SINGLE INSTITUTIONAL
EXPERIENCE. Indian Journal of Medical and Paediatric Oncology.April- june 2010.Vol 31.Issue 2.Page 51-53.

• Hepatoblastoma: Experience from a single center. Indian Journal of Cancer. July-Sept 2010; 47(3):314-6.

• Primary B cell non-Hodgkin’s lymphoma of tongue. Letter to the editor. Indian J Cancer. Jan-March 2010; 47(1):84-6.
• Rectal carcinoma metastasizing to the breast: A case report and review of literature. Journal of Cancer Research and Therapeutics – October-December 2009 – Volume 5 – Issue 4.310-312.
• Turbid serum in a patient of ALL on treatment. What to look for? Letter to the editor. Journal of Cancer Research and Therapeutics.Vol.5 Issue 3.July-Sept.2009.Page 219-220

• Blindness as an initial presentation of rectal cancer with brain metastases. Letter to the editor. The Saudi Journal of Gastroenterology.Vol.15.Number 1. Jan 2009.Page 63-64.
• IgA Plasma cell Leukemia. Journal of Laboratory Physicians. Jan-Jun 2009.Vol 1.Issue 1.Page 19-21.
• Use of Port-A-Cath in pediatric cancer patients: Experience from a tertiary cancer center in south India. J Clin Oncol 27, 2009 (suppl; abstr e20747).
• Age and gender as influencing factor on treatment outcome in extensive stage small cell lung cancer (SCLC).Abstract P-40 (411-Abs- 360).Indian Journal of Cancer.Vol.45.Supp.Oct 2009.
• Use of long term venous access in cancer patients: Experience from a tertiary cancer centre in South India. J Clin Oncol 26: 2008 (May 20 suppl; abstr 20710)
• Drug induced Hepatitis: The commonest culprit in clinical practice. The Journal of General Medicine. April-June 2005.Vol.17 No.2.Page 29-33.
• Significance of t (8: 14) in CLL? Letter to Editor. Indian Journal of Human Genetics.

Publications-others

Acute myeloid leukemia following radioactive iodine therapy for papillary carcinoma of the thyroid. Turk J Hematol 2009; 26: 97-9
• A clinical study of bone metastases in carcinoma lung. Abstract P-38 (413-Abs-454). Indian Journal of Cancer.Vol.45.Supp.Oct 2009.
• To analyze efficacy, safety and toxicity profile of Docetaxel- carboplatin vs. gemcitabine-carboplatin in advanced NSCLC. Abstract P-5 (410-Abs-379). Indian Journal of Cancer.Vol.45.Supp.Oct 2009.
• Combination therapy with docetaxel and carboplatin in advanced NSCLC in elderly (>65 yr) – Experience from a tertiary care center from South India. Abstract P-1 (412-Abs-362). Indian Journal of Cancer.Vol.45.Supp.Oct 2009.

• HIV related malignancies: a single centre experience. Abstract P-3505. European Journal of Cancer. Supplements, Vol 7 No 2, September 2009, Page 203.
• A comparative study of single-dose pegfilgrastim versus daily filgrastim in patients with acute myeloid leukemia. Abstract No: e18005: J Clin Oncol 27, 2009 (suppl; abstr e18005)

• To analyze efficacy and safety of pegfilgrastim versus filgrastim in patients with breast cancer .J Clin Oncol 27, 2009 (suppl; abstr e20587)

• Retrospective analysis of clinico-pathological profile of triple negative breast cancer – Experience from a tertiary care center from South India. The Breast 2009.Vol 18(Suppl 1).S71.0210

• The efficacy, toxicity profile and tolerability of cisplatin plus 5-FU versus docetaxel plus carboplatin as induction therapy in locally advanced oral cancer: an experience from a tertiary cancer centre from South India. J Clin Oncol 26: 2008 (May 20 suppl; abstr 17017)
• Dose escalation of imatinib in CML patients with sub-optimal response to conventional dosage: Is it worth it? J Clin Oncol 26: 2008 (May 20 suppl; abstr 18026)
• Nail changes induced by weekly Paclitaxel as a surrogate marker for response assessment in patients with metastatic breast cancer. J Clin Oncol 26: 2008 (May 20 suppl; abstr 12019)
• To analyze the efficacy, tolerability, toxicity profile, and pharmaco- economics of Paclitaxel-Carboplatin vs. Cisplatin-Etoposide in patients with advanced NSCLC. Journal of Thoracic Oncology • Vol. 3, No. 4, Supplement 1, 2008.
• Retrospective analysis of incidences of visceral and non visceral metastasis in triple negative and non triple negative breast cancer patients – Experience from a tertiary care center from South India. Asia–Pac J Clin Oncol 2008; 4(Suppl. 2): A114.

Posters

Can early monocytopenia predict the risk of neutropenia after chemotherapy? ISMPOCON 2009,Srinagar
• HER-2 as a predictive marker in tailoring chemotherapies in resource poor countries in node negative, hormone receptor negative and HER- 2 positive tumors.PSIV-62 at ISMPO 2009, Chennai.

• A Clinical profile of patients with diffuse large B cell Lymphoma. PSIII- 58 at ISMPO 2009,Chennai
• HIV related hematological malignancies from regional cancer center. ISMPOCON2009, Srinagar.

Thesis/Dissertation

Thesis entitled “Platelet Dysfunction in Valvular /Congenital Heart diseases” for MD (Medicine) degree, Jan 2006, University of Mumbai

Clinical research Co-Investigator:

A Randomized open label, Multicenter, phase 3 study of Epoetin alfa Plus standard supportive care versus standard supportive care in anemic Patients with metastatic breast caner receiving first line standard Chemotherapy.(Johnson & Johnson, USA)

• A Randomized, double blind, multicenter study of Denosumab compared with zolendronic acid (zometa) in the treatment of bone metastasis in subjects with advanced breast cancer. (Amgen Inc, USA)

• A Phase 3, Multicenter, Randomized placebo controlled, Double blind trial of AMG 706 in combination with Paclitaxel and Carboplatin for Advanced Non small cell lung cancer. (Amgen Inc, USA)

• A Phase 2, Multicenter, Open Label, Randomized Trial of AMG 706 or Bevacizumab in Combination with Paclitaxel and Carboplatin for Advanced Non-squamous Non-small Cell Lung Cancer (Amgen Inc, USA)

• A pivotal phase 3 observer blind, randomized clinical trial of the efficacy and safety of APF530 compared to ALOXI® for the prevention of acute onset and delayed onset chemotherapy induced nausea and vomiting following the administration of either moderately or highly emetogenic chemotherapy regimens.
• A Randomized, 4-arm, placebo-controlled phase 2 trial of AMG 386 in combination with bevacizumab and paclitaxel as first line chemotherapy in subjects with Her2-negative, metastatic or locally recurrent breast cancer (Amgen Inc, USA)
• A Randomized, Double-Blind, Placebo Controlled, Phase 2 Trial of paclitaxel in combination with AMG 386 in subjects with Advanced

Recurrent Epithelial Ovarian or Primary Peritoneal Cancer (Amgen Inc, USA)

• A Phase II Randomized Double Blind, Placebo Controlled Study of AMG 786 in Combination with FOLFIRI in Subjects with previously treated Metastatic Colorectal Carcinoma (Amgen Inc, USA)

• A Multi-center, placebo-controlled, Randomized phase 2 Trial of Motesanib in combination with Gemcitabine & cisplatin in First line Treatment of Subjects with Advanced Non-Small Cell Lung Cancer.

• A Multicenter, Double-Blind, 3-Arm, Phase 1b/2 Study in Subjects with Unresectable Locally Advanced or Metastatic Gastric or Esophagogastric Junction Adenocarcinoma to Evaluate the Safety and Efficacy of First-line Treatment with Epirubicin, Cisplatin, and Xeloda (ECX)+15 mg/kg AMG 102 or ECX+7.5 mg/kg AMG 102 or ECX Alone. (Amgen Inc, USA)
• A Phase 1b/ 2 Trial of AMG 479 or AMG 102 in Combination with Platinum- based Chemotherapy as First-Line Treatment for Extensive Stage Small Cell Lung Cancer.(Amgen Inc, USA)
• An International, Multicenter, Randomized, Double-Blind Study of Vorinostat (MK-0683) or Placebo in Combination with Bortezomib in Patients with Multiple Myeloma-(MK-0683-088)

Good Clinical Practices (GCP) Training

GCP in Investigator Meeting for AVE 5026 (Sanofis Aventis), June 2007, Hong Kong
GCP in Investigator Meeting for AMG protocol 20070307 (Amgen Inc, USA), Nov 2008, Mumbai.

Lectures and Moderation-More than 100…some are given below

1. Maintenance therapy in NSCLC;Is the more better?23rd May ,MENA Oncology Conference, Cairo, Egypt,Nov 2011

2.Angiogenesis Inhibitors and its role in second line setting in lung cancer. 9th UAE Cancer Congress, Dubai, UAE,5th oct 2017

3.Moderator, Immunotherapy and targeted therapy-How do we integrate in guidelines and practice. 9th UAE Cancer Congress, Dubai, UAE,5th oct 2017

4.Moderator.Panel discussion on metastatic prostate cancer. Oct 2019,3rd Annual International Precision Oncology and breast cancer Conference, Jaipur

5.Neoadjuvant treatment Gastric Cancer.4th AMMO conference,Aug 2018

6.Cancer cachexia anorexiaBest of MASCC sept 2019,TMH

7.Newer Concepts in Colorectal Cancer prevention.1st FPIC 2016 on colorectal Cancer

8.Perioperative chemotherapy in resectable colorectal cancer with liver mets.EBM,TMH feb 2024

9. Role of Liquid biopsy in BTC.6th Annual asia pacific cholangiocarcinoma conference,Nov 2023

10.Moderator,Dual Her2 blockade in adjuvant breast cancer;are we convinced,April 2024